Exenatide safe, effective for hospitalized patients with T2D

  • Fayfman M & al.
  • Diabetes Care
  • 24 Jan 2019

  • curated by Miriam Tucker
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Short-acting exenatide (Byetta), alone or with basal insulin, is safe and improves glycemic control in general medicine and surgery inpatients with type 2 diabetes (T2D).

Why this matters

  • Guidelines recommend basal-bolus insulin regimens for hospitalized patients with T2D, but these regimens are inconvenient and can cause hypoglycemia.

Study design

  • Multicenter, open-label trial, 150 patients with blood glucose (BG) 140-400 mg/dL randomly assigned to receive 5 μg twice daily exenatide alone or combined with basal insulin alone or basal-bolus regimen.
  • Funding: AstraZeneca.

Key results

  • Overall mean hospital BGs:
    • exenatide alone: 177.1 mg/dL;
    • exenatide+basal-bolus: 166.1 mg/dL; and
    • exenatide+basal insulin: 154.1 mg/dL (P=.03 overall).
  • Proportion of readings in target 70-180 mg/dL range:
    • exenatide: 62.3%;
    • exenatide+basal-bolus: 63.3%; 
    • exenatide+basal insulin: 77.7% (P=.005 vs basal-bolus; P=.07 vs exenatide alone).
  • Hypoglycemia (BG
  • exenatide: 0%;
  • exenatide+basal-bolus: 12%; and 
  • exenatide+basal insulin: 6% (P=.06 overall).
  • Nausea and vomiting, respectively (n):
    • exenatide: 5 and 1;
    • exenatide+basal-bolus: 1 and 0; and
    • exenatide+basal insulin: 5 and 3 (P=.017 overall).
  • 3 participants (all exenatide alone) discontinued because of gastrointestinal side effects (P=.029).
  • No significant differences in hospital length of stay (exenatide+basal 5.0 vs exenatide alone 4.0 vs exenatide+basal-bolus 4.0 days; P=.23).
  • Limitations

    • Small sample sizes.
    • No masking.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.